172 related articles for article (PubMed ID: 38627904)
21. Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy.
Kirshner J; Hatch M; Hennessy DD; Fridman M; Tannous RE
Oncologist; 2004; 9(1):25-32. PubMed ID: 14755012
[TBL] [Abstract][Full Text] [Related]
22. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
[TBL] [Abstract][Full Text] [Related]
23. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
[TBL] [Abstract][Full Text] [Related]
24. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Slamon DJ; Leyland-Jones B; Shak S; Fuchs H; Paton V; Bajamonde A; Fleming T; Eiermann W; Wolter J; Pegram M; Baselga J; Norton L
N Engl J Med; 2001 Mar; 344(11):783-92. PubMed ID: 11248153
[TBL] [Abstract][Full Text] [Related]
25. Donepezil Protects Against Doxorubicin-Induced Chemobrain in Rats via Attenuation of Inflammation and Oxidative Stress Without Interfering With Doxorubicin Efficacy.
Ongnok B; Khuanjing T; Chunchai T; Pantiya P; Kerdphoo S; Arunsak B; Nawara W; Jaiwongkam T; Apaijai N; Chattipakorn N; Chattipakorn SC
Neurotherapeutics; 2021 Jul; 18(3):2107-2125. PubMed ID: 34312765
[TBL] [Abstract][Full Text] [Related]
26. The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment.
Butterfield DA
Free Radic Biol Med; 2014 Sep; 74():157-74. PubMed ID: 24996204
[TBL] [Abstract][Full Text] [Related]
27. Anthracyclines React with Apurinic/Apyrimidinic Sites in DNA.
Bellamri M; Terrell JT; Brandt K; Gruppi F; Turesky RJ; Rizzo CJ
ACS Chem Biol; 2023 Jun; 18(6):1315-1323. PubMed ID: 37200590
[TBL] [Abstract][Full Text] [Related]
28. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
;
Lancet; 2023 Apr; 401(10384):1277-1292. PubMed ID: 37061269
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
[TBL] [Abstract][Full Text] [Related]
30. L-carnitine Modulates Cognitive Impairment Induced by Doxorubicin and Cyclophosphamide in Rats; Insights to Oxidative Stress, Inflammation, Synaptic Plasticity, Liver/brain, and Kidney/brain Axes.
Morid OF; Menze ET; Tadros MG; George MY
J Neuroimmune Pharmacol; 2023 Sep; 18(3):310-326. PubMed ID: 37140732
[TBL] [Abstract][Full Text] [Related]
31. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
Somlo G; Doroshow JH; Forman SJ; Leong LA; Margolin KA; Morgan RJ; Raschko JW; Akman SA; Ahn C; Nagasawa S
Cancer; 1994 Mar; 73(6):1678-85. PubMed ID: 7512436
[TBL] [Abstract][Full Text] [Related]
32. A Review on the Neurotoxic Effects of Doxorubicin.
Kamińska K; Cudnoch-Jędrzejewska A
Neurotox Res; 2023 Oct; 41(5):383-397. PubMed ID: 37351828
[TBL] [Abstract][Full Text] [Related]
33. Toxicity profile of Doxorubicin-Cyclophosphamide and Doxorubicin-Cyclophosphamide followed by Paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: A prospective cohort study.
Gadisa DA; Assefa M; Wang SH; Yimer G
J Oncol Pharm Pract; 2020 Dec; 26(8):1912-1920. PubMed ID: 32122234
[TBL] [Abstract][Full Text] [Related]
34. Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer.
Wong AL; Sundar R; Wang TT; Ng TC; Zhang B; Tan SH; Soh TI; Pang AS; Tan CS; Ow SG; Wang L; Mogro J; Ho J; Jeyasekharan AD; Huang Y; Thng CH; Chan CW; Hartman M; Iau P; Buhari SA; Goh BC; Lee SC
Oncotarget; 2016 Sep; 7(39):64089-64099. PubMed ID: 27577069
[TBL] [Abstract][Full Text] [Related]
35. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer.
Himmel LE; Lustberg MB; DeVries AC; Poi M; Chen CS; Kulp SK
Exp Toxicol Pathol; 2016 Oct; 68(9):505-515. PubMed ID: 27555377
[TBL] [Abstract][Full Text] [Related]
36. Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line therapy in metastatic breast cancer: a retrospective analysis.
Livi L; Meattini I; Cardillo Cde L; Mangoni M; Greto D; Petrucci A; Rampini A; Bruni A; Galardi A; Cataliotti L; Biti G
Tumori; 2009; 95(4):422-6. PubMed ID: 19856650
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Mackey JR; Martin M; Pienkowski T; Rolski J; Guastalla JP; Sami A; Glaspy J; Juhos E; Wardley A; Fornander T; Hainsworth J; Coleman R; Modiano MR; Vinholes J; Pinter T; Rodríguez-Lescure A; Colwell B; Whitlock P; Provencher L; Laing K; Walde D; Price C; Hugh JC; Childs BH; Bassi K; Lindsay MA; Wilson V; Rupin M; Houé V; Vogel C;
Lancet Oncol; 2013 Jan; 14(1):72-80. PubMed ID: 23246022
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of reduced dose of pegfilgrastim in Japanese breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide therapy.
Mizuno Y; Fuchikami H; Takeda N; Iwai M; Sato K
Jpn J Clin Oncol; 2017 Jan; 47(1):12-17. PubMed ID: 28122890
[TBL] [Abstract][Full Text] [Related]
40. N-Acetylcysteine Attenuates the Anxiety-Like Behavior and Spatial Cognition Impairment Induced by Doxorubicin and Cyclophosphamide Combination Treatment in Rats.
Kitamura Y; Ushio S; Sumiyoshi Y; Wada Y; Miyazaki I; Asanuma M; Sendo T
Pharmacology; 2021; 106(5-6):286-293. PubMed ID: 33352577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
